In this study, for the population of infracentimetric tumours, the HER-2+ status was an independent variable for prognosis with a relative risk of recurrence of 4.6 (confidence interval (CI) 95% 1.0–20.6) and death of 11.1 (CI 95% 1.0–122.8) when comparing HER-2+ with HER-2- tumours [23]. Here, ERBB2 is linked to neoplasm.